0.630
-0.03 (-4.40%)
| Penutupan Terdahulu | 0.659 |
| Buka | 0.660 |
| Jumlah Dagangan | 50,607 |
| Purata Dagangan (3B) | 312,562 |
| Modal Pasaran | 19,565,406 |
| Harga / Buku (P/B) | 2.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Aug 2023 - 14 Aug 2023 |
| EPS Cair (TTM) | -0.580 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.09% |
| Nisbah Semasa (MRQ) | 11.01 |
| Aliran Tunai Operasi (OCF TTM) | -19.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.27 M |
| Pulangan Atas Aset (ROA TTM) | -46.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Inhibikase Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.38 |
|
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (PD), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.02% |
| % Dimiliki oleh Institusi | 74.49% |
| Julat 52 Minggu | ||
| Median | 4.00 (534.92%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 11 Dec 2025 | 4.00 (534.92%) | Beli | 1.50 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |